Tunicamycin 是一种同源核苷抗生素的混合物, 可抑制 N-糖基化并阻断GlcNAc磷酸转移酶 (GPT)。Tunicamycin 引起细胞内质网 (ER) 中未折叠蛋白的积累并诱导 ER 应激,并导致 DNA 合成受阻和 G1 期细胞周期停滞。Tunicamycin 可抑制革兰氏阳性细菌,酵母,真菌和病毒,并具有抗癌活性。Tunicamycin 增加宫颈癌细胞中外泌体的释放。
生物活性 | Tunicamycin is a mixture of homologous nucleosideantibioticthat inhibitsN-linked glycosylationand blocksGlcNAc phosphotransferase (GPT). Tunicamycin causes accumulation of unfolded proteins in cell endoplasmic reticulum (ER) and induces ER stress, and causes blocking of DNA synthesis and cell cycle arrest in G1 phase. Tunicamycin inhibitsgram-positive bacteria,yeasts,fungi, andvirusesand has anti-cancer activity[1][2][3].Tunicamycin increases exosome release in cervicalcancercells[4]. |
体外研究 (In Vitro) | Tunicamycin (2 μg/mL; 24 hours; CD44+/CD24- and original MCF7 cells) treatment increases the spliced XBP-1, ATF6 nuclear translocation level and CHOP protein expression in CD44+/CD24- and original MCF7 cells[1]. Tunicamycin-induced ER stress suppresses CD44+/CD24- phenotype cell subpopulation and in vitro invasion and accelerates tumorosphore formation. Under effect of Tunicamycin, the results show that inhibited invasion, increased cell death, suppressed proliferation and reduced migration in the CD44+/CD24- and CD44+/CD24- rich MCF7 cell culture[1].
Western Blot Analysis Cell Line: | CD44+/CD24- and original MCF7 cells[1] | Concentration: | 2 μg/mL | Incubation Time: | 24 hours | Result: | Increased level of spliced XBP-1, ATF6 nuclear translocation and CHOP protein expression are detected in CD44+/CD24- and original MCF7 cells. |
|
体内研究 (In Vivo) | Tunicamycin (0.1 mg/kg or 0.5 mg/kg) treatment dramatically suppresses tumor growth in the CD133+/-MHCC97L cells xenograft model (BALB/c (nu/nu) mice)[2].
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | - Antibiotics
- Other Antibiotics
|
来源 | Streptomyces lysosuperficus |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 33.33 mg/mL(Need ultrasonic) H2O :< 0.1 mg/mL(insoluble) In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2 mg/mL (Infinity mM); Clear solution
此方案可获得 ≥ 2 mg/mL (Infinity mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2 mg/mL (Infinity mM); Clear solution
此方案可获得 ≥ 2 mg/mL (Infinity mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2 mg/mL (Infinity mM); Clear solution
此方案可获得 ≥ 2 mg/mL (Infinity mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|